Skip to content

ELAN changes

Pick any two versions below to diff them.

View the full Nov 13, 2026 version
Price
$25.77
Discount category
Close to intrinsic value
Next earnings
Feb 23, 2027
Next earnings is estimate
Yes
Company name
added: Elanco Animal Health
Sector
added: Veterinary medicines
About
added: Elanco Animal Health Incorporated (Elanco) is based in Indianapolis, Indiana. It develops, makes and sells medicines, vaccines and other products for pets and farm animals. Its Pet Health brands include Zenrelia, Credelio Quattro, Advantage and Seresto. Its Farm Animal products serve cattle, poultry and swine. Revenue was $1,265 million in Q3 2026: Pet Health $608 million, Farm Animal $631 million and contract manufacturing and other $26 million. In April 2026 it bought AHV International, a Dutch farm animal health company. Elanco pays no dividend. The common stock trades on the NYSE in US dollars. Elanco files 10-K and 10-Q reports.
Thesis
added: The price of Elanco depends on whether its new pet products keep growth and margins up while the company pays down the debt from earlier purchases. Revenue grew 9% in Q3 2026 on an organic constant currency basis, with price up 4%, and the adjusted gross margin rose 300 basis points to 56.1%. Zenrelia and Credelio Quattro gained share in the US, and Credelio Quattro became its largest US Pet Health brand. The net leverage ratio fell to 2.9 times adjusted EBITDA at September 30, 2026, from 3.6 times at the end of 2025. For the price to hold or rise, three things must be true. Zenrelia, Credelio Quattro and the new product Befrena must keep gaining share against strong competitors. Elanco must reach its 2026 guidance of adjusted EBITDA of $1,050 million to $1,065 million and then its 2027 outlook of high-single-digit adjusted EBITDA growth and low-double-digit adjusted EPS growth. Free cash flow must keep reducing the debt, so that interest costs fall. The Q4 2026 report, expected in late February 2027, with 2027 guidance, and the EU launch of Credelio Quattro in Q1 2027 are the next tests.
Risks
added: Debt is high. Debt principal was $3,470 million at September 30, 2026, and net interest expense was $59 million in Q3 2026. Lower earnings would slow the payback of debt. Pet Health products face strong competitors, also in the markets of Zenrelia and Credelio Quattro, and from generic products. Lost share would slow growth. Elanco faces lawsuits. A securities class action says that Elanco made false or misleading statements about the safety and label of Zenrelia, and other lawsuits allege unlawful sales practices for flea and tick products. Farm animal sales depend on disease and farm economics. Poultry revenue fell 7% in Q3 2026, and an outbreak of disease could cut demand. Changes in tariffs, trade rules and exchange rates can change costs and reported revenue.
Balance sheet
added: Cash: $465M Debt: $3.5B Net debt: $3.0B EBITDA, last 12 months: $1.1B Net debt / EBITDA: 2.9× (medium) Undrawn credit line: $750M, to July 2029 Debt due within 12 months: $74M Last debt due: 2032 At September 30, 2026, Elanco had debt principal of $3,470 million: term loans of $2,620 million, Senior Notes due 2028 of $750 million at 6.40% and $100 million under its securitization facility. Finance lease liabilities were $258 million. Cash and cash equivalents were $465 million. Elanco gives net debt of $3,005 million and a net leverage ratio of 2.9 times trailing adjusted EBITDA of $1,053 million. The $750 million revolving credit facility, which matures in July 2029, had no borrowings. With interest rate swaps, the weighted average interest rate was 5.26%. Operating cash flow was $506 million for nine months. The balance sheet also has a liability for sale of future revenue of $309 million, for royalties that Elanco sold to Blackstone in May 2025. As of Sep 30, 2026.
Checkpoints
added: Feb 23, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: 2026 adjusted EBITDA is in the guided range of $1,050 million to $1,065 million and 2027 guidance keeps high-single-digit adjusted EBITDA growth, and this passes; a result below the range or lower 2027 growth fails. Q1 2027 (estimate): EU launch of Credelio Quattro. Pending. Watch: Elanco launches Credelio Quattro in the EU in Q1 2027, as it expects, and this passes; a delay past Q2 2027 fails.
Recent events
added: Nov 6, 2026: Elanco reported Q3 2026 results. Revenue rose 11% to $1,265 million, or 9% on an organic constant currency basis, adjusted EBITDA rose 23% to $243 million and adjusted EPS was $0.27. It raised 2026 guidance to revenue of $5,155 million to $5,180 million, adjusted EBITDA of $1,050 million to $1,065 million and adjusted EPS of $1.17 to $1.20. Nov 6, 2026: Elanco said that Credelio Quattro received a positive opinion from the European Medicines Agency, and it expects to launch the product in the EU in Q1 2027. It also said that Befrena moves into full launch in Q1 2027. Nov 3, 2026: Jamie Preston became Executive Vice President and Chief People Officer. Dave Kinard, who held the role, plans to retire at the end of 2026. Apr 30, 2026: Elanco completed the purchase of AHV International, a Dutch farm animal health company that works to reduce the need for antibiotics, for an estimated total price of $241 million. Dec 5, 2025: The board approved a restructuring plan that cuts about 300 jobs and moves about 300 more to growth areas or lower-cost places, with pretax charges of about $175 million.